Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ZYME

Zymeworks BC Inc

Apr 28 • 04:00PM ET

27.94

-0.62 -2.17 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: AMGN BIIB GILD REGN VRTX INCY ALNY EXEL NBIX IONS

| Held by: VTI IWM IBB IWO VTWO DFAS FYC DFMC IWC FYX

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	5.75%	Shs Outstand	74.64M	Perf Week	-1.17%
Market Cap	2.08B	Forward P/E	92.26	EPS next Y	0.30	Insider Trans	-4.21%	Shs Float	70.03M	Perf Month	15.55%
Enterprise Value	1.87B	PEG	-	EPS next Q	-0.30	Inst Own	97.53%	Short Float	6.64%	Perf Quarter	20.17%
Income	-81.13M	P/S	19.59	EPS this Y	209.81%	Inst Trans	-5.48%	Short Ratio	7.24	Perf Half Y	57.50%
Sales	105.97M	P/B	7.82	EPS next Y	-74.47%	ROA	-20.04%	Short Interest	4.65M	Perf YTD	6.11%
Book/sh	3.57	P/C	9.07	EPS next 5Y	-	ROE	-26.72%	52W High	29.75 -6.08%	Perf Year	116.93%
Cash/sh	3.08	P/FCF	-	EPS past 3/5Y	- 21.35%	ROIC	-28.64%	52W Low	10.86 157.27%	Perf 3Y	232.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-36.43% 22.16%	Gross Margin	89.81%	Volatility	4.75% 4.06%	Perf 5Y	-12.25%
Dividend TTM	-	EV/Sales	17.60	EPS Y/Y TTM	33.39%	Oper. Margin	-87.34%	ATR (14)	1.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.88	Sales Y/Y TTM	38.87%	Profit Margin	-76.56%	RSI (14)	59.14	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.88	EPS Q/Q	-73.76%	SMA20	3.18%	Beta	1.23	Target Price	40.08
Payout	-	Debt/Eq	0.07	Sales Q/Q	-91.90%	SMA50	11.09%	Rel Volume	0.66	Prev Close	28.56
Employees	264	LT Debt/Eq	0.06	Earnings	May 07 AMC	SMA200	34.11%	Avg Volume	642.87K	Price	27.94
IPO	Apr 28, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.28% -86.93%	Trades		Volume	421,291	Change	-2.17%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$33
Dec-03-25	Initiated	Citizens JMP	Mkt Outperform	$32
Oct-24-25	Resumed	Wells Fargo	Equal Weight	$15
Oct-14-25	Upgrade	H.C. Wainwright	Neutral → Buy	$26
Oct-10-25	Initiated	B. Riley Securities	Buy	$30
May-20-25	Initiated	TD Cowen	Buy
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight	$18
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform	$10 → $25
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$12
Mar-21-23	Resumed	Wells Fargo	Overweight	$12
Jan-04-23	Reiterated	H.C. Wainwright	Neutral	$10 → $8
Dec-20-22	Upgrade	Jefferies	Hold → Buy	$7.70 → $11
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral	$40 → $8
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$8
Oct-04-22	Resumed	Wells Fargo	Overweight	$45 → $9
May-05-22	Upgrade	Guggenheim	Neutral → Buy	$14
Mar-15-22	Initiated	Evercore ISI	Outperform	$15
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold	$32

Show Previous Ratings

Apr-21-26 05:30PM	Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 (GlobeNewswire)
Apr-17-26 03:00PM	Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform (GlobeNewswire)
Apr-16-26 06:00AM	Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026 (GlobeNewswire)
Apr-09-26 06:00AM	Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth (GlobeNewswire)
Apr-01-26 06:00AM	Zymeworks Appoints Kristin Stafford as Chief Financial Officer (GlobeNewswire)
06:00AM	Loading…
Mar-30-26 06:00AM	Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRa-Targeting Antibody-Drug Conjugate (GlobeNewswire)
Mar-24-26 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Mar-18-26 07:46AM	Zymeworks Announces Presentations for Ziihera (zanidatamab-hrii) at 2026 AACR Annual Meeting (GlobeNewswire)
Mar-17-26 05:02PM	Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting (GlobeNewswire)
Mar-02-26 04:01PM	Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience (GuruFocus.com)
10:37AM	Zymeworks Q4 Earnings Call Highlights (MarketBeat)
08:30AM	Zymeworks Inc. Q4 2025 Earnings Call Summary (Moby)
07:15AM	Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:01AM	Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing (GlobeNewswire)
06:00AM	Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
12:15PM	Loading…
Feb-25-26 12:15PM	Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates (Zacks)
Feb-12-26 06:00AM	Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 (GlobeNewswire)
Jan-27-26 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-12-26 06:00AM	Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy (GlobeNewswire)
Jan-11-26 06:00PM	Zymeworks Outlines Strategic Priorities and Outlook for 2026 (GlobeNewswire)
Jan-09-26 12:19PM	Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 (MarketBeat)
Jan-06-26 01:34PM	Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit (GlobeNewswire) -5.10%
Dec-03-25 09:35AM	Oracle initiated, Uber upgraded: Wall Street's top analyst calls (The Fly)
Dec-02-25 04:05PM	Zymeworks Announces Participation in Upcoming Conferences (GlobeNewswire)
Nov-24-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-18-25 12:16PM	JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data (Zacks)
03:38AM	Zymeworks to change course, pursue royalty-driven biotech model (BioPharma Dive)
01:01AM	Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer (GlobeNewswire)
01:00AM	Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets (GlobeNewswire)
Nov-17-25 04:13PM	Stocks to Watch Recap: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal) +29.05%
09:35AM	Loading…
09:35AM	Stocks to Watch Monday: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal)
09:02AM	Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer (Investor's Business Daily)
08:10AM	Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. (Barrons.com)
06:00AM	Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GlobeNewswire)
Nov-06-25 05:35PM	Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.04%
04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-30-25 10:00AM	Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 12:00PM	Zymeworks (ZYME) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Oct-28-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Oct-23-25 12:30PM	Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-? at AACR-NCI-EORTC Conference (GlobeNewswire)
Oct-16-25 09:55AM	Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 25.73%: Here's is How to Trade (Zacks)
06:00AM	Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025 (GlobeNewswire)
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
Oct-14-25 12:00PM	Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy? (Zacks)
Oct-13-25 04:00PM	Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International Conference (GlobeNewswire)
Oct-10-25 03:20PM	Bitcoin Miner Leads Two Health Care Stocks To New Highs (Investor's Business Daily) +6.74%
09:36AM	Align downgraded, NetEase upgraded: Wall Street's top analyst calls (The Fly)
Oct-09-25 08:30AM	InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors (Newsfile)
06:00AM	Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer (GlobeNewswire)
Sep-02-25 12:30PM	Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit (Benzinga) -5.40%
06:00AM	Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager (GlobeNewswire)
Aug-19-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 11:41AM	Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Aug-12-25 10:26AM	Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
09:55AM	Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-11-25 06:00AM	Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry (GlobeNewswire)
Aug-07-25 06:35PM	Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-29-25 11:03AM	Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More (GlobeNewswire)
Jul-28-25 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate (GlobeNewswire)
Jul-18-25 09:58AM	Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains? (Zacks)
Jul-17-25 06:00AM	Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 (GlobeNewswire) +7.10%
Jul-10-25 12:00PM	Life Sciences BC Announces 2025 Awards Winners, Honouring Excellence in Health Innovation (Business Wire)
Jun-20-25 12:00PM	All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy (Zacks)
Jun-04-25 09:55AM	Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? (Zacks)
May-30-25 06:00AM	Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer (GlobeNewswire)
May-22-25 05:00PM	Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences (GlobeNewswire)
May-21-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-19-25 04:15PM	Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference (GlobeNewswire) +5.16%
May-14-25 09:55AM	Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet (Zacks)
May-08-25 05:50PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 10:35AM	Zymeworks Inc (ZYME) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-30-25 06:33PM	Hope Amidst The Madness As Market Avoids A New Low (Seeking Alpha)
Apr-28-25 05:33PM	Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline (Seeking Alpha)
10:48AM	Zymeworks: Poised For Growth With Platform Validation (Seeking Alpha)
Apr-25-25 01:00PM	Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting (GlobeNewswire)
Apr-21-25 06:00AM	Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development (GlobeNewswire)
Apr-17-25 06:00AM	Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 (GlobeNewswire)
Apr-09-25 10:13AM	Zymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump's Tariff Rollout (Insider Monkey)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-26-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-25 04:30PM	Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting (GlobeNewswire)
10:49AM	Zymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-05-25 04:05PM	Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -7.97%
Mar-04-25 07:09AM	Zymeworks Inc (ZYME) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-26-25 06:00AM	Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration (GlobeNewswire)
Feb-25-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Feb-18-25 06:00AM	Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors (GlobeNewswire)
Feb-13-25 06:00AM	Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025 (GlobeNewswire)
Jan-30-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-08-25 04:05PM	Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 (GlobeNewswire) -6.44%
Dec-12-24 08:30AM	Zymeworks Hosts RandD Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases (GlobeNewswire)
08:30AM	Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases (GlobeNewswire)
Nov-21-24 06:05AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -5.98%
06:00AM	FDA Grants U.S. Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) (GlobeNewswire)
Nov-05-24 06:00AM	Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-? Expressing Advanced Solid Tumors (GlobeNewswire)
Oct-31-24 04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:14AM	Zymeworks Inc (ZYME) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jeffrey T L Smith	Former Officer	Mar 06 '26	Proposed Sale	24.80	247,333	6,133,858		Mar 06 09:00 PM
Leone D Patterson	Former officer	Feb 17 '26	Proposed Sale	22.60	31,641	715,087		Feb 17 09:00 PM
Leone D Patterson	Former officer	Feb 13 '26	Proposed Sale	23.17	128,548	2,978,457		Feb 13 09:00 PM
Hollywood Mark	EVP & Chief Operating Officer	Jan 12 '26	Option Exercise	0.00	17,666	0	139,033	Jan 13 05:11 PM
Hollywood Mark	EVP & Chief Operating Officer	Jan 12 '26	Sale	22.67	6,120	138,762	132,913	Jan 13 05:11 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 12 '26	Option Exercise	0.00	17,666	0	36,018	Jan 12 09:00 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 12 '26	Sale	22.67	9,310	211,090	26,708	Jan 12 09:00 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 12 '26	Option Exercise	0.00	17,666	0	58,057	Jan 12 08:32 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 12 '26	Sale	22.67	9,560	216,759	48,497	Jan 12 08:32 PM
Galbraith Kenneth	Chair & CEO	Jan 12 '26	Option Exercise	0.00	64,000	0	257,266	Jan 12 07:07 PM
Galbraith Kenneth	Chair & CEO	Jan 12 '26	Sale	22.67	30,424	689,819	226,842	Jan 12 07:07 PM
Leone D Patterson	Former officer	Jan 12 '26	Proposed Sale	23.17	6,832	158,297		Jan 12 05:00 PM
Kenneth Galbraith	Officer	Jan 12 '26	Proposed Sale	23.17	30,424	704,924		Jan 12 05:00 PM
Paul Andrew Moore	Officer	Jan 12 '26	Proposed Sale	23.17	9,560	221,505		Jan 12 05:00 PM
Jeffrey T L Smith	Officer	Jan 12 '26	Proposed Sale	23.17	9,310	215,713		Jan 12 05:00 PM
Mark Hollywood	Officer	Jan 12 '26	Proposed Sale	23.17	6,120	141,800		Jan 12 05:00 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 05 '26	Option Exercise	0.00	20,000	0	28,890	Jan 05 08:22 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 05 '26	Sale	25.10	10,538	264,471	18,352	Jan 05 08:22 PM
Galbraith Kenneth	Chair & CEO	Jan 05 '26	Option Exercise	0.00	114,334	0	224,952	Jan 05 08:20 PM
Galbraith Kenneth	Chair & CEO	Jan 05 '26	Sale	25.10	54,343	1,363,841	158,286	Jan 05 08:20 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 05 '26	Option Exercise	0.00	37,168	0	51,212	Jan 05 08:18 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 05 '26	Sale	25.10	20,110	504,699	31,212	Jan 05 08:18 PM
Smith Jeffrey T L	Officer	Jan 05 '26	Proposed Sale	26.62	10,538	280,522		Jan 05 07:00 PM
Kenneth Galbraith	Officer	Jan 05 '26	Proposed Sale	26.62	54,343	1,446,611		Jan 05 07:00 PM
Paul Andrew Moore	Officer	Jan 05 '26	Proposed Sale	26.62	20,110	535,328		Jan 05 07:00 PM
Galbraith Kenneth	Chair & CEO	Dec 22 '25	Option Exercise	0.00	100,000	0	180,803	Dec 22 05:52 PM
Galbraith Kenneth	Chair & CEO	Dec 22 '25	Sale	27.02	47,528	1,284,311	133,275	Dec 22 05:52 PM
Galbraith, Kenneth	Officer	Dec 22 '25	Proposed Sale	27.23	47,528	1,294,187		Dec 22 05:00 PM
Derek John Michael Miller	Former Director	Nov 24 '25	Proposed Sale	23.82	118,000	2,810,760		Nov 24 08:00 PM
Neil Gallagher	Former Director	Nov 21 '25	Proposed Sale	23.82	105,000	2,501,100		Nov 21 08:00 PM
EcoR1 Capital, LLC	Director	May 15 '25	Buy	11.43	49,502	565,847	17,877,989	May 19 06:35 PM
EcoR1 Capital, LLC	Director	May 19 '25	Buy	11.78	5,919	69,738	17,883,908	May 19 06:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZYME

Zymeworks BC Inc

Upgrade your Finviz experience